Table 1.
Patient sample characteristics: ibrutinib sensitivity, IgVH mutation status, diabetic status, Clinical Status, RAI stage, del13q14 status, and del17p status.
| Patient # | Ibrutinib sensitivity | IgVH status | Diabetic status | Clinical status | RAI stage | Del13q status | Del17p status |
|---|---|---|---|---|---|---|---|
| 1 | Sen | M | N | T | III | + | – |
| 2 | Sen | M | N | NA | IV | NA | – |
| 3 | Sen | M | D | T | O | + | – |
| 4 | Sen | M | H | T | IV | + | – |
| 5 | Sen | M | NA | T | NA | NA | – |
| 6 | Sen | U | N | NT | I | + | – |
| 7 | Sen | U | N | NT | II | + | – |
| 8 | Sen | U | N | NT | II | – | – |
| 9 | Sen | U | D | NA | NA | + | – |
| 10 | Sen | U | NA | NT | II | + | – |
| 11 | Sen | U | NA | NT | NA | – | – |
| 12 | Res | M | N | T | II | – | – |
| 13 | Res | M | N | T | II | + | – |
| 14 | Res | M | N | T | III | – | – |
| 15 | Res | M | N | NT | IV | + | – |
| 16 | Res | M | N | NA | NA | + | – |
| 17 | Res | M | D | NT | III | – | – |
| 18 | Res | M | NA | NT | II | – | – |
| 19 | Res | M | NA | NT | NA | + | – |
| 20 | Res | U | N | NA | I | – | – |
| 21 | Res | U | N | NT | IV | – | – |
| 22 | Res | U | N | T | IV | – | – |
| 23 | Res | U | N | NT | NA | – | – |
| 24 | Res | U | D | NA | IV | – | – |
| 25 | Res | U | NA | T | II | – | – |
| 26 | Res | U | NA | T | NA | – | – |
| 27 | Sen | M | NA | NT | II | NA | + |
| 28 | Sen | NA | NA | T | NA | + | + |
| 29 | Sen | NA | NA | NT | NA | NA | + |
| 30 | Res | M | NA | T | I | + | + |
Sen, Sensitive; Res, Resistant; D, Diabetic; H-High glucose; N, Non-diabetic; NA-Not available; M-Mutated; U-Unmutated; T-patients clinically treated; NT-patients not clinically treated; del13q-del13q14. All samples are negative for del11q deletion and naïve for ibrutinib treatment or other tyrosine kinase inhibitors.